Literature DB >> 27697553

Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.

Erika Pike1, William W Stoops2, Craig R Rush3.   

Abstract

There is not an approved pharmacotherapy for treating methamphetamine use disorder. This study sought to determine the effects of acute buspirone treatment on the subjective and cardiovascular effects of oral methamphetamine in order to provide an initial assessment of the utility, safety, and tolerability of buspirone for managing methamphetamine use disorder. We predicted that acute buspirone administration would reduce the subjective effects of methamphetamine. We also predicted that the combination of buspirone and methamphetamine would be safe and well tolerated. Ten subjects completed the protocol, which tested three methamphetamine doses (0, 15, and 30mg) in combination with two buspirone doses (0 and 30mg) across 6 experimental sessions. Subjective effects and physiological measures were collected at regular intervals prior to and after dose administration. Methamphetamine produced prototypical subjective and cardiovascular effects. Acute buspirone administration increased some of the abuse-related subjective effects of methamphetamine and also attenuated some cardiovascular effects. The combination of oral methamphetamine and buspirone was safe and well tolerated. Acute buspirone administration may increase the abuse liability of oral methamphetamine. Chronic buspirone dosing studies remain to be conducted, but given preclinical findings and the outcomes of this work, the utility of buspirone for treating methamphetamine use disorder appears limited. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute; Buspirone; Cardiovascular effects; Methamphetamine; Subjective effects

Mesh:

Substances:

Year:  2016        PMID: 27697553      PMCID: PMC5145756          DOI: 10.1016/j.pbb.2016.09.009

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  46 in total

1.  Influence of acute bupropion pre-treatment on the effects of intranasal cocaine.

Authors:  William W Stoops; Joshua A Lile; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  Addiction       Date:  2012-02-11       Impact factor: 6.526

Review 2.  New insights into the mechanism of action of amphetamines.

Authors:  Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

3.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

4.  Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.

Authors:  William W Stoops; Erika Pike; Lon R Hays; Paul E Glaser; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2014-11-29       Impact factor: 3.533

5.  Effects of buprenorphine on the self-administration of cocaine by humans.

Authors:  R.W. Foltin; M.W. Fischman
Journal:  Behav Pharmacol       Date:  1994-02       Impact factor: 2.293

6.  Methamphetamine self-administration by humans.

Authors:  C L Hart; A S Ward; M Haney; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-08       Impact factor: 4.530

7.  Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans.

Authors:  M Haney; A S Ward; R W Foltin; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

Review 8.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

Review 9.  Approaches to the development of medications for the treatment of methamphetamine dependence.

Authors:  Frank J Vocci; Nathan M Appel
Journal:  Addiction       Date:  2007-04       Impact factor: 6.526

10.  Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.

Authors:  Walter Ling; Linda Chang; Maureen Hillhouse; Alfonso Ang; Joan Striebel; Jessica Jenkins; Jasmin Hernandez; Mary Olaer; Larissa Mooney; Susan Reed; Erin Fukaya; Shannon Kogachi; Daniel Alicata; Nataliya Holmes; Asher Esagoff
Journal:  Addiction       Date:  2014-07-08       Impact factor: 6.526

View more
  2 in total

Review 1.  Unpredictability as a modulator of drug self-administration: Relevance for substance-use disorders.

Authors:  Sally L Huskinson
Journal:  Behav Processes       Date:  2020-06-08       Impact factor: 1.777

2.  Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine.

Authors:  Anna R Reynolds; Justin C Strickland; William W Stoops; Joshua A Lile; Craig R Rush
Journal:  Drug Alcohol Depend       Date:  2017-09-22       Impact factor: 4.492

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.